Saturday 17 October 2026
Export ACOG’s income statement to Excel — free account
Alpha Cognition Inc.
ACOG Healthcare Biotechnology
Alpha Cognition Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million. In the quarter to June 2026, revenue grew 267.6%, EPS grew 38.5% and free cash flow fell 109.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.19
0.26
−3.08%
Follow ACOG
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
10.30 | 11.04 | 11.24 | 0.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(22.92) | (10.13) | (16.64) | (19.87) | |
P/B ratio |
2.97 | 2.08 | 1.84 | 3.10 | |
Price to Tangible BV |
3.36 | 2.09 | 1.85 | 3.14 | |
EV/Sales |
7.65 | 6.11 | 4.87 | 0.00 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.78) | (2.20) | (2.44) | (4.48) | |
EV/FCF |
(3.15) | (2.18) | (2.40) | (4.42) | |
Quick Ratio |
7.32 | 10.67 | 7.70 | 5.61 | |
Current Ratio |
9.03 | 12.64 | 8.65 | 6.69 | |
Net Debt/EBITDA |
5.42 | 6.73 | 12.09 | 6.69 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.28 | 0.18 | 0.16 | 0.00 | |
Operating CF/Net income |
0.78 | 1.82 | 1.56 | 4.01 | |
Capex/Depreciation |
(57.97) | (0.04) | (5.42) | (5.95) | |
Interest Coverage |
— | — | — | 14.06 | |
Research and Development Expense of Revenue |
32.97% | 31.02% | 17.46% | 20.19% | |
Selling, General and Administrative Expense of Revenue |
187.91% | 290.24% | 270.10% | 244.49% | |
Intangible Assets out of Total Assets |
0.10 | 0.01 | 0.00 | 0.01 | |
Share Based Compensation of Revenue |
27.87% | 23.36% | 33.85% | (47.69%) | |
Graham Net Nets |
0.30 | 0.48 | 0.54 | 0.32 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(14.96%) | (24.23%) | (17.85%) | (21.04%) | |
Free Cash Flow Yield |
(23.59%) | (25.46%) | (18.03%) | (15.22%) | |
Revenue per Share |
0.28 | 0.16 | 0.16 | 0.18 | |
Operating CF per Share |
(0.31) | (0.54) | (0.39) | (0.33) | |
Capex per Share |
(0.28) | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.59) | (0.54) | (0.40) | (0.33) | |
Cash per Share |
1.90 | 2.50 | 3.74 | 2.20 | |
Shareholders Equity per Share |
2.43 | 2.64 | 3.54 | 2.10 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.43 | 2.64 | 3.54 | 2.10 | |
Free Cash Flow |
(12.86) | (11.80) | (7.05) | (5.36) | |
Working Capital |
51.51 | 63.13 | 69.88 | 38.87 | |
Capital Expenditures |
(6.01) | 0.00 | (0.15) | (0.07) | |
Net Current Asset Value |
46.37 | 56.77 | 61.81 | 33.31 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.99 | 0.00 | 0.05 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.64 | 2.00 | 2.15 | 1.45 | |
Average Payables |
4.52 | 3.94 | 5.71 | 4.14 | |
Average Inventory |
3.64 | 3.46 | 2.87 | — | |
Average Assets |
54.82 | 58.93 | 65.23 | 25.66 | |
Average Common Equity |
42.43 | 49.13 | 50.81 | 15.50 |
Columns are period end dates